secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ovid Therapeutics Inc. (OVID)
CIK:        0001636651
Form:       8-K
Filed at:   2022-03-15T23:59:59+00:00
Accession:  0000950170-22-003665
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ovid Therapeutics reduces workforce 20%, extends cash runway beyond 2024; OV329 on track for 2022 clinical entry
--------------------------------------------------------------------------------

- Workforce reduced by ~20% to extend cash runway beyond 2024 as part of organizational restructuring.
- OV329, a GABA aminotransferase inhibitor, expected to enter clinical trials in 2022 for tuberous sclerosis seizures.
- Takeda to present pivotal Phase 3 soticlestat results in Dravet and Lennox-Gastaut syndromes in 2023.
- Financial results for Q4/FY2021 reported but specific figures not provided in filing excerpt; focus on cost reduction.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636651/000095017022003665/0000950170-22-003665-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636651/000095017022003665/ovid-20220315.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-003665

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer